New Diagnostic 98% Accurate Detecting Early Stage Ovarian Cancers
Diagnostics developer HealthLinx Limited has completed an initial Phase II biomarker trial on its ovarian cancer diagnostic that has increased the efficiency of the panel to 98% for early stage diagnosis.
Read More